Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hCT-MSC in Children With Autism Spectrum Disorder
NCT03099239Phase 1Completed
- Sponsor
- Joanne Kurtzberg
- Start
- Jun 2017
- Primary completion
- Jun 2019
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of wharton's jelly mesenchymal stromal cells in Autism Spectrum Disorder (ASD) (3 arms), sponsored by Joanne Kurtzberg. Primary endpoints: Incidence of Infusion reactions at 12 months and Incidence of Infections at 12 months. Started Jun 2017; status: completed.
02
Drugs
wharton's jelly mesenchymal stromal cells
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT03099239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03099239.